Duchenne muscular dystrophy (DMD) is a genetic disease characterized by muscle degeneration and weakness. DMD affects 1 in every 3,500 boys and is caused by a mutation in the gene encoding a protein, dystrophin, which provides structural stability to muscle fibers. DMD patients exhibit muscle atrophy at a young age, which gets progressively worse over time. The final stages of the disease are characterized by severe muscle degeneration, loss of mobility, cardiorespiratory failure, and death, generally before age 30 years.
Sarcopenia is the age-related degeneration of muscle characterized and one of the leading causes of disability in the elderly resulting in a loss of independence, increased risk of falls, fractures, and physical disability. Although the impact of sarcopenia on healthcare costs and the quality of life of the aging population is being widely recognized, there are currently no approved therapeutics to treat it.
Local muscle atrophy
Localized muscle atrophy can be severely disabling and there are no treatment options. The Myoforte strategy addresses atrophy of muscles in the hand due to carpal tunnel syndrome, wasting of shoulder muscles after rotator cuff tear, and weakness of muscles after a hip fracture. Muscle loss in patients with neuromuscular diseases like Charcot-Marie-Tooth disease and Facioscapulohumeral Muscular Dystrophy may also be addressed with our therapy. Additionally, patients with stress urinary incontinence, ptosis, and facial palsy could benefit from our proposed therapy.